Literature DB >> 6975246

Antibodies in human sera to F(ab')2 fragments of monoclonal and polyclonal IgG.

N R Ling, P Drysdale.   

Abstract

F(ab')2 fragments of human, bovine and rabbit polyclonal IgG and of human IgG paraproteins of different subclass and light-chain type have been coupled to human red cells and used to detect "agglutinator' antibodies in normal and pathological human sera. The common occurrence of such antibodies in human sera and their heterogeneity in terms of specificity have been confirmed. No change in titre or specificity was found in monoclonal B cell proliferations. The possible significance of serum agglutinators is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975246     DOI: 10.1159/000232854

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  8 in total

1.  Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.

Authors:  J C Cordy; P J Morley; T J Wright; M A Birchler; A P Lewis; R Emmins; Y Z Chen; W M Powley; P J Bareille; R Wilson; J Tonkyn; A I Bayliffe; A L Lazaar
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

2.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

3.  IgG binding of monoclonal anti-nuclear antibodies from MRL-lpr/lpr mice.

Authors:  D S Pisetsky; B S Darwin; C F Reich
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

4.  Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Authors:  Karen Thudium Mueller; Stephan A Grupp; Shannon L Maude; John E Levine; Michael A Pulsipher; Michael W Boyer; Keith J August; G Doug Myers; Constantine S Tam; Ulrich Jaeger; Stephen Ronan Foley; Peter Borchmann; Stephen J Schuster; Edmund K Waller; Rakesh Awasthi; Bernd Potthoff; Andy Warren; Edward R Waldron; Fraser McBlane; Andrea Chassot-Agostinho; Theodore W Laetsch
Journal:  Blood Adv       Date:  2021-12-14

5.  Serum IgG4 anti-Fab antibodies in rheumatoid arthritis are constitutively expressed.

Authors:  J E Persselin; R H Stevens
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa.

Authors:  C Christopoulos
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

7.  Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis.

Authors:  J E Persselin; R H Stevens
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

8.  Pre-existing canine anti-IgG antibodies: implications for immunotherapy, immunogenicity testing and immunoassay analysis.

Authors:  Daniel Bergman; Camilla Bäckström; Helene Hansson-Hamlin; Anders Larsson; Bodil Ström Holst
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.